US Election 2016
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
US President-elect Donald Trump is expected to work closely with congressional leadership on health care issues, potentially including drug pricing, but uncertainty is always the watchword with Trump.
Latest From US Election 2016 &BioPharmaceutical
Allergan, Pfizer, Bristol-Myers Squibb, AbbVie, GSK, Sanofi and Roche showed glimpses in recent earnings calls of potential impacts on their global manufacturing networks from a US plan to legislate border-adjusted tax cuts. But there was not a word about President Trump’s threat of tariffs.
Less than a month after his inauguration, President Donald Trump has both unnerved and empowered industry sectors with his immediate actions or divulged potential reforms. Execs offered measured reaction and some speculation during recent earnings calls.
Former US FDA Commissioner Mark McClellan suggests the key with agency regulations may be how they are interpreted, and providing predictability and clarity, rather than just the scope of what’s written.
Novartis CEO Jimenez suggests Trump Administration may help remove regulatory barriers to US outcome-based contracting between manufacturers and payers; Duke Margolis Center for Health Policy plans policy initiative to promote value-based purchasing for drugs, medical devices and gene therapy.
Medicaid rebates have been a fact of life in the pharmaceutical industry for 25 years. But the Affordable Care Act repeal-and-replace debate may open up the possibility of eliminating the mandatory rebates – and the requirement that all drugs be covered by the program.
Followers of rogue FDA twitter site AltFDA answered a call to back up inspection citations data the Obama administration made public in case the Trump administration erases it from the FDA website.
Lower taxes could entice biopharmaceutical sector to focus more on the US as it seeks to expand biotech manufacturing capacity where it can find highly educated and experienced scientists.
Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.
Alzheimer drug’s development was discontinued after third disappointing Phase III trial, but given the kind of FDA commissioner candidates getting meetings with the President, maybe Lilly should reconsider.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.